drugset / Trial / NCT01025284

A Study for Participants With Small-Cell Lung Cancer

NCT01025284

Phase 2 Completed 64 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Part A: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer. Part B: This study evaluates an experimental treatment in participants with extensive-disease in small-cell lung cancer.

Timeline

Start
2009-12
Primary completion
2012-07
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject litronesib Small molecule 5 mg/m2 Intravenous
Subject litronesib Small molecule 6 mg/m2 Intravenous
Subject litronesib Small molecule 8 mg/m2 Intravenous